Type 2 diabetes and HbA1c targets.
The Accord and Advance trials each involved more than 10 000 patients and lasted several years. Detailed results of these studies have now been published. They do not challenge the existing HbA1c target of 7% for most patients with type 2 diabetes.
D000419:Albuminuria; D002318:Cardiovascular Diseases / Q000150:complications / Q000401:mortality; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D003925:Diabetic Angiopathies / Q000517:prevention & control*; D003928:Diabetic Nephropathies / Q000517:prevention & control*; D006442:Glycated Hemoglobin; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced / Q000401:mortality; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents